Back

Adimmune CDMO orders surge 50%, supporting full-year profit goal

Verifying
  • Adimmune said expanding CDMO operations could support a return to full-year profitability.
  • CDMO order volume rose 50% year over year after the second line began production.
  • Adimmune reported NT$555 million in first-eight-month revenue, up 12.6% year over year.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.